<DOC>
	<DOC>NCT02959463</DOC>
	<brief_summary>The goal of this clinical research study is to assess the safety of pembrolizumab (also called MK-3475) after radiation therapy (with or without surgery and/or chemotherapy) in patients with MPM.</brief_summary>
	<brief_title>Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>Study Groups: If you are found to be eligible to take part in this study, you will be assigned to 1 of 2 groups. Your doctor will decide which group you are in. Up to 12 participants will be enrolled in each group. If you are enrolled in Group A, you will have already received at least 2 cycles of chemotherapy and possibly lung-sparing surgery. You will then receive radiation therapy to one side of your chest, or thorax, a technique called "hemithoracic radiation." You will then receive pembrolizumab. If you are enrolled in Group B, you may or may not have had chemotherapy or immunotherapy. You will not have received surgery. You will receive radiation therapy over a course of 1-3 weeks to a region that does not include the entire side of your chest, or thorax. You will then receive pembrolizumab. Study Drug Administration: In both groups, you will receive pembrolizumab by vein over about 30 minutes on Day 1 of each 3-week cycle after radiation therapy, for up to 2 years. Study Visits: When you are not receiving radiation, you will have these visits about every 3 weeks while you receive immunotherapy: - You will have a physical exam. - Blood (about 1-2 tablespoons) will be drawn to check your immune system, for side effects, and to check the status of the disease. You will have a CT and/or PET scan to check the status of the disease before radiation therapy, at Cycle 4, and then every 3 cycles thereafter. If the doctor thinks it is needed, you may have extra imaging. You will have a PFT to check your lung function at Cycle 7 and then every 6 cycles. End-of-Study Visit: When you stop receiving the study drug: - You will have a physical exam. - Blood (about 1-2 tablespoons) will be drawn to check your immune system, for side effects, and to check the status of the disease. - You will have a PFT to check your lung function. Length of Study: You may continue taking the study drug for up to 2 years. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. If the disease appears to be getting worse or the tumors appear to be getting larger, you may still be able to receive the study drug if you and your doctor decide it is in your best interest. Sometimes the disease appears to get worse but the study drug is actually working. However, there are risks of continuing to receive the study drug because the disease may actually be getting worse. You are still at risk for side effects due to the study drug. This could also delay starting other treatments. The disease may get worse to the point that you are no longer able to receive other treatments. If you choose to receive the study drug after the disease gets worse, you will continue to have study visits as described above. The study doctor will discuss this option with you. Your participation on the study will be over after the follow-up visits. Follow Up: About 30 days after your last dose of study drug, you will have a physical exam. About every 12 weeks after your last dose of pembrolizumab: - You will have a physical exam. - You may have CT or PET scans to check the status of the disease. - If your doctor thinks it is needed, blood (about 1 tablespoon) may be drawn for routine tests. - At Weeks 12 and 24, you will have PFTs performed. If you are unable to make these visits, you will be contacted by phone to check your health. This is an investigational study. Radiation therapy is delivered using FDA-approved and commercially available methods for local control of metastatic and primary tumors. Pembrolizumab is FDA approved and commercially available for the treatment of unresectable or metastatic melanoma, and for lung cancer. Its use in this study is investigational. Up to 24 participants will take part in this study. All will be enrolled at MD Anderson.</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1. Patients must have a histologic diagnosis of malignant pleural mesothelioma 2. Be willing and able to provide written informed consent/assent for the trial. 3. Be &gt;/= 18 years of age on day of signing informed consent. 4. Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. 5. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newlyobtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newlyobtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from Merck. 6. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. 7. Demonstrate adequate organ function as described, all screening labs should be performed within 10 days of treatment initiation: HEMATOLOGICAL: Absolute neutrophil count (ANC) &gt;/=1,500 /mcL; Platelets &gt;/= 100,000 / mcL; Hemoglobin &gt;/= 9 g/dL or &gt;/= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment); RENAL: Serum creatinine &lt;/= 1.5 X upper limit of normal (ULN) or Measured or calculated creatinine clearance (glomerular filtration rate (GFR) can also be used in place of creatinine or creatinine clearance (CrCl)) &gt;/=60 mL/min for subject with creatinine levels &gt; 1.5 X institutional ULN; 8. Inclusion #6 continuedHEPATIC: Serum total bilirubin &lt;/= 1.5 X ULN or Direct bilirubin &lt;/= ULN for subjects with total bilirubin levels &gt; 1.5 ULN; aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) &lt;/= 2.5 X ULN or &lt;/= 5 X ULN for subjects with liver metastases; Albumin &gt;/= 2.5 mg/dL; COAGULATION: International Normalized Ratio (INR) or Prothrombin Time (PT) &lt;/= 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants; Activated Partial Thromboplastin Time (aPTT) &lt;/= 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants 9. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 10. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for &gt; 1 year. 11. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy. 12. *Additional Inclusion Criteria COHORT 1 (Patients Receiving Hemithoracic Radiation Therapy): *1. Patients must not have evidence of metastatic disease per PET/CT scan. Mediastinal lymph node involvement is acceptable. *2. Patients will have received at least 2 cycles of induction chemotherapy with pemetrexed/cisplatin or pemetrexed/carboplatin. *3. The following pulmonary function tests are required: a. Forced expiratory volume in 1 second (FEV1)&gt;/=30% of predicted postoperative (ppoFEV1, as if patient underwent a pneumonectomy) based on the following formula using a quantitative perfusion scan: Predicted postresection FEV1=FEV1 x % perfusion to the uninvolved lung from the quantitative perfusion report. b. Diffusing capacity of the lungs for carbon monoxide (DLCO)&gt;35% predicted. 13. Continued Additional Inclusion Criteria COHORT 1: Patients must be assessed to be a suitable candidate for hemithoracic radiation therapy per the treating radiation oncologist. If the patient undergoes pleurectomy/decortication, they must initiate hemithoracic radiation therapy within 4 months of the surgery date. Patients that do not meet the dose constraints outlined below will be removed from the study prior to radiation therapy. 14. *Additional Inclusion Criteria COHORT 2: *1. Patients must be assessed to be a suitable candidate for radiation therapy by the treating radiation oncologist. Patients that do not meet the dose constraints outlined below will be removed from the study prior to radiation therapy. *2. Any prior number of prior therapies, including prior immunotherapy, is allowed. *3. Patient must have prior treatment with a platinum plus pemetrexed regimen. 1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. 2. Has a diagnosis of immunodeficiency. Note that patients should not receive steroids during Pembrolizumab administration. 3. Has a known history of active tuberculosis (TB) (Bacillus Tuberculosis) 4. Hypersensitivity to pembrolizumab or any of its excipients. 5. Has had a prior anticancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., &lt;/= Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. 6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 and who have not recovered adequately from this treatment (&lt;/=Grade 2 toxicity at the time of enrollment). 7. Has a known additional malignancy that is progressing or requires active treatment. Patients with a stage IIII cancer that has been cured over two years ago are not excluded in the study. 8. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability. 9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 10. Has a history of (noninfectious) pneumonitis that required steroids or current pneumonitis. 11. Has an active infection requiring systemic therapy. 12. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 13. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the prescreening or screening visit through 120 days after the last dose of trial treatment. 14. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). 15. Has known active Hepatitis B (e.g., hepatitis B surface antigen (HBsAg) reactive) or Hepatitis C (e.g., hepatitis C virus (HCV) ribonucleic acid (RNA) [qualitative] is detected). 16. Has received a live vaccine within 30 days of planned start of study therapy. *Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., FluMistÂ®) are live attenuated vaccines, and are not allowed. 17. Evidence of interstitial lung disease. 18. *Additional Exclusion Criteria COHORT 1: Patients undergoing an extrapleural pneumonectomy (EPP). Lung sparing surgeries, such as pleurectomy/decortication, are acceptable. 19. Additional Exclusion Criteria COHORT 1: Has received prior therapy with an antiPD1, antiPDL1, or antiPDL2 agent. 20. Additional Exclusion Criteria COHORT 2: *1. Patients in which hemithoracic radiation therapy is planned. *2. Patients who have received P/D or EPP for mesothelioma. 21. Additional Exclusion Criteria Cohorts 1 and 2: 1. Patients with inherited syndromes associated with hypersensitivity to ionizing radiation, specifically patients with known history of AtaxiaTelangiectasia, Nijmegen breakage syndrome.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Malignant pleural mesothelioma</keyword>
	<keyword>MPM</keyword>
	<keyword>Non-metastatic</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>Keytruda</keyword>
	<keyword>MK-3475</keyword>
	<keyword>SCH-900475</keyword>
	<keyword>Radiation therapy</keyword>
	<keyword>Radiation treatment</keyword>
	<keyword>XRT</keyword>
	<keyword>Intensity modulated radiation therapy</keyword>
	<keyword>IMRT</keyword>
	<keyword>Proton beam therapy</keyword>
	<keyword>PBT</keyword>
	<keyword>3D conformal therapy</keyword>
</DOC>